Retatrutide Phase 3 program reports top-line results
What company-reported Phase 3 results do and do not mean while retatrutide remains investigational.
By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.
The milestone
Lilly reported top-line Phase 3 results from TRIUMPH-1 in adults with obesity or overweight and at least one weight-related comorbidity but without diabetes. The company described average body-weight reductions through 80 weeks, with variation across assigned trial groups.
ClinicalTrials.gov lists TRIUMPH-1 as completed, while TRIUMPH-Outcomes and TRIUMPH-5 remain active-not-recruiting records designed to answer longer-term cardiovascular, kidney, and head-to-head comparison questions.
Why it matters
- Top-line Phase 3 findings are a meaningful milestone after earlier Phase 2 research, but they are still company-reported summaries until full peer-reviewed results and regulatory reviews are available.
- Large, longer trials can answer questions that shorter studies cannot, including uncommon harms, durability, and whether changes in weight or biomarkers lead to meaningful health outcomes.
What it means for readers
- The page should no longer describe the whole Phase 3 program as only awaiting efficacy confirmation; at least some top-line Phase 3 results have now been reported by the sponsor.
- Nothing changed for routine patient care: retatrutide remains an investigational drug without an FDA-approved product.
- Readers should avoid treating company summaries, planned timelines, or trial registration as equivalent to approval or a complete published benefit-risk profile.
What remains uncertain?
- How the full Phase 3 data will read after peer-reviewed publication
- The full safety profile in larger and longer studies
- What indication, label, or formulation regulators might consider if a future application is submitted
- Whether outcomes, head-to-head, and longer-duration studies will confirm durable clinical benefit
Related fact sheets
Source links
- 1company releaseLilly: TRIUMPH-1 top-line Phase 3 results
Company-reported Phase 3 obesity results; not a peer-reviewed publication or FDA approval.
- 2clinical trialsClinicalTrials.gov: TRIUMPH-1
Completed Phase 3 master trial record for obesity with knee-osteoarthritis and obstructive-sleep-apnea substudies.
- 3clinical trialsClinicalTrials.gov: TRIUMPH-5
Registered Phase 3 comparison with tirzepatide in adults with obesity.
- 4
- 5pubmedNEJM Phase 2 retatrutide trial indexed in PubMed
Peer-reviewed dose-finding obesity trial that preceded the Phase 3 program.